Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TONIC-3 trial in advanced triple-negative breast cancer
NL-OMON60716Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by Netherlands Cancer Institute. Primary endpoints: Progression-free survival rate at 12 weeks and Adverse events. Started Jun 2024; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON60716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60716.